Role of Paracetamol in PDA Closure
Paracetamol is an effective alternative to traditional cyclooxygenase inhibitors (indomethacin/ibuprofen) for closing patent ductus arteriosus in preterm infants, with comparable efficacy and a superior safety profile, particularly regarding gastrointestinal and renal adverse effects.
Evidence Quality and Strength
The evidence base consists primarily of research-level data, as no specific guidelines address paracetamol for PDA closure. The most compelling recent evidence comes from:
- A 2026 randomized trial 1 demonstrating that prolonged low-dose paracetamol prophylaxis significantly accelerates ductal closure in extremely preterm infants (median closure time 3 days vs 14 days, p=0.031)
- A 2021 randomized controlled trial 2 stopped early for benefit, showing 38% absolute risk reduction in need for PDA intervention (NNT=2.6)
- A 2018 Cochrane review 3 of 916 infants providing moderate-quality evidence of equivalence to ibuprofen
Clinical Efficacy
Compared to Ibuprofen
Paracetamol demonstrates equivalent efficacy to ibuprofen for ductal closure, with no significant difference in failure rates (RR 0.95% CI 0.75-1.21) 3. A small study reported 100% effectiveness (86% complete closure, 14% hemodynamic closure) 4.
Compared to Indomethacin
No significant difference in PDA closure rates (RR 0.96,95% CI 0.55-1.65) 3.
Prophylactic Use
Early prophylactic paracetamol shows borderline superiority over placebo/no intervention (RR 0.49,95% CI 0.24-1.00; NNT=5) 3. The 2026 trial 1 strengthens this finding with 75% vs 35% closure rates in extremely preterm infants.
Safety Advantages
Paracetamol demonstrates clear safety benefits over traditional agents:
- Reduced gastrointestinal bleeding: 72% risk reduction vs ibuprofen (RR 0.28,95% CI 0.12-0.69; NNT=17) 3
- Better renal function: Lower serum creatinine levels and higher urine output compared to both ibuprofen and indomethacin 3
- Higher platelet counts: Reduced thrombocytopenia risk 3
- Lower bilirubin levels: Compared to ibuprofen 3
No adverse events were reported in the 2026 trial 1 or the small 2024 study 4.
Dosing Regimens
Therapeutic Treatment
- Loading dose: 15-20 mg/kg IV
- Maintenance: 7.5 mg/kg IV every 6 hours
- Duration: 3-9 days depending on protocol 4, 2, 1
Prophylactic Treatment
The 2026 trial 1 used 20 mg/kg loading dose followed by 7.5 mg/kg every 6 hours for 9 days, started before 96 hours of age.
Critical Caveats
Neurodevelopmental Concerns
Important limitation: Concerns exist regarding prenatal/postnatal paracetamol exposure and autism spectrum disorder 3. Only one small study (n=61) assessed long-term outcomes at 18-24 months, finding no differences but providing low-quality evidence 3. Long-term follow-up to at least 18-24 months must be incorporated in clinical practice when using paracetamol.
Monitoring
Routine serum paracetamol concentration monitoring is not recommended based on 2026 data showing no association with closure rates, toxicity detection, or cost-effectiveness (£120.72 per actionable result) 5. Use selective, indication-based monitoring only.
Population Gaps
Paucity of data exists for infants at the border of viability (≤25 weeks gestation) 6.
Clinical Algorithm
For hemodynamically significant PDA in preterm infants:
First-line therapy: Paracetamol 15-20 mg/kg loading, then 7.5 mg/kg q6h for 3-5 days
- Equivalent efficacy to traditional agents
- Superior safety profile
- Particularly advantageous if contraindications to NSAIDs exist (thrombocytopenia, renal dysfunction, GI concerns)
Rescue therapy: Paracetamol for persistent PDA after failed cyclooxygenase inhibitor treatment 6
Prophylactic use: Consider in extremely preterm infants (<28 weeks) starting before 96 hours of age for 9 days 1
Monitoring: Clinical assessment and echocardiography; avoid routine serum drug levels 5
Follow-up: Mandatory neurodevelopmental assessment at 18-24 months given theoretical concerns 3